<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00825162</url>
  </required_header>
  <id_info>
    <org_study_id>CSLCT-USF-06-29</org_study_id>
    <nct_id>NCT00825162</nct_id>
  </id_info>
  <brief_title>Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged &gt;= 6 Months to &lt; 18 Years</brief_title>
  <official_title>A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged &gt;= 6 Months to &lt; 18 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability Profile of
      CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged &gt;= 6 Months to &lt; 18
      Years
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and Intensity of Local and Systemic Solicited Adverse Events, Cohort A (6 Months to Less Than 3 Years)</measure>
    <time_frame>7 days post-vaccination</time_frame>
    <description>Solicited Local Adverse Events: pain, redness, and swelling/induration. Solicited Systemic Adverse Events: fever, headache, myalgia, nausea/vomiting, diarrhea, loss of appetite, and irritability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Local and Systemic Solicited Adverse Events, Cohort A (6 Months to Less Than 3 Years)</measure>
    <time_frame>7 days post-vaccination</time_frame>
    <description>Solicited Local Adverse Events: pain, redness, and swelling/induration. Solicited Systemic Adverse Events: fever, headache, myalgia, nausea/vomiting, diarrhea, loss of appetite, and irritability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and Intensity of Local and Systemic Solicited Adverse Events, Cohort B (3 Years to Less Than 9 Years)</measure>
    <time_frame>7 days post-vaccination</time_frame>
    <description>Solicited Local Adverse Events: pain, redness, and swelling/induration. Solicited Systemic Adverse Events: fever, headache, myalgia, nausea/vomiting, diarrhea, and malaise.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Local and Systemic Solicited Adverse Events, Cohort B (3 Years to Less Than 9 Years)</measure>
    <time_frame>7 days post-vaccination</time_frame>
    <description>Solicited Local Adverse Events: pain, redness, and swelling/induration. Solicited Systemic Adverse Events: fever, headache, myalgia, nausea/vomiting, diarrhea, and malaise.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and Intensity of Local and Systemic Solicited Adverse Events, Cohort C (9 Years to Less Than 18 Years)</measure>
    <time_frame>7 days post-vaccination</time_frame>
    <description>Solicited Local Adverse Events: pain, redness, and swelling/induration. Solicited Systemic Adverse Events: fever, headache, myalgia, nausea/vomiting, diarrhea, and malaise.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Local and Systemic Solicited Adverse Events, Cohort C (9 Years to Less Than 18 Years)</measure>
    <time_frame>7 days post-vaccination</time_frame>
    <description>Solicited Local Adverse Events: pain, redness, and swelling/induration. Solicited Systemic Adverse Events: fever, headache, myalgia, nausea/vomiting, diarrhea, and malaise.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Unsolicited Adverse Events (UAEs)</measure>
    <time_frame>30 days after each study vaccination</time_frame>
    <description>UAE stands for Unsolicited Adverse Event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Serious Adverse Events</measure>
    <time_frame>180 days after the last study vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of New Onsets of Chronic Illness</measure>
    <time_frame>180 days after the last study vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1992</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 6 months to less than 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 3 years to less than 9 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 9 years to less than 18 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL Limited Influenza Virus Vaccine</intervention_name>
    <description>Single or two-vaccination regimen (0.25mL)</description>
    <arm_group_label>Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL Limited Influenza Virus Vaccine</intervention_name>
    <description>Single or two-vaccination regimen (0.5mL)</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL Limited Influenza Virus Vaccine</intervention_name>
    <description>Single vaccination regimen (0.5mL)</description>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female participants aged ≥ 6 months to &lt; 18 years at the time of
             vaccination;

          2. Written informed consent to participate in the study and adherence to all protocol
             requirements. Consent will be obtained from the participant, parent or guardian as
             appropriate according to the applicable Independent Ethics Committee (IEC) and local
             requirements. Participant assent will also be obtained if required by the applicable
             IEC;

          3. Good health, as determined by medical history, and a targeted physical examination;

          4. For participants aged &lt; 9 years, born after a normal gestation period (between 36 and
             42 weeks);

          5. Females of childbearing potential (defined as having experienced their first menstrual
             cycle) must be abstinent or be using adequate contraceptive precautions e.g.
             intrauterine contraceptive device, oral contraceptive, or equivalent hormonal
             contraception (e.g., progestogen-only implant, vaginal contraceptive ring, cutaneous
             hormonal patch or injectable contraceptives) for at least 2 months after vaccination.
             Females aged ≥ 9 years must also return a negative urine pregnancy test at enrolment.

        Exclusion Criteria:

          1. Known hypersensitivity to a previous dose of influenza vaccine or allergy to eggs,
             chicken protein, neomycin, polymyxin, or any components of the Study Vaccine;

          2. Clinical signs of significant active infection and/or an elevated temperature (≥
             38.0°C oral or ≥ 37.5°C axillary) at study entry;

          3. Vaccination against influenza virus in the previous 6 months with a seasonal IVV;

          4. Vaccination with an experimental IVV (e.g. a candidate pandemic IVV or a novel IVV) in
             the previous 6 months;

          5. Females of child bearing potential, planning to become pregnant or planning to
             discontinue contraceptive precautions within 2 months of vaccination;

          6. Pregnant or lactating females;

          7. Clinically significant medical or psychiatric conditions, as follows:

               -  For acute conditions (active or recent), the condition required hospitalisation
                  within the last month; or

               -  For chronic conditions: the Investigator feels that the chronic condition is
                  unstable, such as illness exacerbations within the previous month:

                  i. requiring hospitalisation; ii. with significant organ function deterioration;
                  iii. with major changes to treatment dosages; iv. requiring major new treatments;
                  or

               -  The Investigator feels the participant has a clinical condition that may be
                  adversely affected through study participation.

          8. Confirmed or suspected immune deficiency (congenital or acquired, including cancer and
             human immunodeficiency virus infection);

          9. History of seizures, with the exception of a past history of a single seizure event at
             any age more than two years previously;

         10. Known history of Guillain-Barré Syndrome;

         11. Current treatment with radiotherapy or cytotoxic drugs, or treatment within the 6
             months prior to administration of the Study Vaccine;

         12. Current (or within the 90 days prior to receiving the Study Vaccine) immunosuppressive
             or immunomodulative therapy, including systemic corticosteroids, as follows:

             • Chronic or long term corticosteroids: i. Age less than 9 years: ≥ 0.5 mg/kg/day of
             oral prednisolone or equivalent daily; ii. Age 9 years and above: ≥ 15 mg/day of oral
             prednisolone or equivalent daily;

             • Sporadic corticosteroids: i. Age less than 9 years: ≥ 1 mg/kg/day of oral
             prednisolone or equivalent for 2 or more short courses of &gt; 3 days in the 3 months
             preceding vaccination; ii. Age 9 years and above: ≥ 40 mg/day of oral prednisolone or
             equivalent for two or more short courses of &gt; 3 days in the 3 months preceding
             vaccination; Note: Use of topical or inhalant corticosteroids prior to administration
             of the Study Vaccine or throughout the Study is acceptable

         13. Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the administration of the Study Vaccine or during the study;

         14. Current treatment with warfarin or other anticoagulants;

         15. Participation in a clinical trial or use of an investigational compound (i.e. a new
             chemical or biological entity not registered for clinical use) within 90 days prior to
             receiving the Study Vaccine or entry into such a study during the on study period;

         16. Evidence, or history (within the previous 12 months) of drug or alcohol abuse;

         17. If, in the Investigator's opinion, the participant should not take part in the
             clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Lambert, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Children's Hospital, Brisbane, Herston, QLD, Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Canberra Hospital</name>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2606</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Clinical Trials Centre</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's &amp; Children's Hospital Adelaide</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murdoch Children's Research Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <results_reference>
    <citation>Lambert SB, Chuk LM, Nissen MD, Nolan TM, McVernon J, Booy R, Heron L, Richmond PC, Walls T, Marshall HS, Reynolds GJ, Hartel GF, Hu W, Lai MH. Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents. Influenza Other Respir Viruses. 2013 Sep;7(5):676-85. doi: 10.1111/irv.12107. Epub 2013 Apr 2.</citation>
    <PMID>23551933</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2009</study_first_submitted>
  <study_first_submitted_qc>January 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2009</study_first_posted>
  <results_first_submitted>July 3, 2011</results_first_submitted>
  <results_first_submitted_qc>July 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 29, 2011</results_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort A</title>
          <description>Participants aged 6 months to less than 3 years, who received one or two doses of the 2009 Southern Hemisphere formulation of CSL Limited Influenza Virus Vaccine.</description>
        </group>
        <group group_id="P2">
          <title>Cohort B</title>
          <description>Participants aged 3 to less than 9 years, who received one or two doses of the 2009 Southern Hemisphere formulation of CSL Limited Influenza Virus Vaccine.</description>
        </group>
        <group group_id="P3">
          <title>Cohort C</title>
          <description>Participants aged 9 to less than 18 years, who received one or two doses of the 2009 Southern Hemisphere formulation of CSL Limited Influenza Virus Vaccine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="710"/>
                <participants group_id="P2" count="880"/>
                <participants group_id="P3" count="402"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="682"/>
                <participants group_id="P2" count="859"/>
                <participants group_id="P3" count="396"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Move away from the study area</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to attend the study visit</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort A</title>
          <description>Participants aged 6 months to less than 3 years, who received one or two doses of the 2009 Southern Hemisphere formulation of CSL Limited Influenza Virus Vaccine.</description>
        </group>
        <group group_id="B2">
          <title>Cohort B</title>
          <description>Participants aged 3 to less than 9 years, who received one or two doses of the 2009 Southern Hemisphere formulation of CSL Limited Influenza Virus Vaccine.</description>
        </group>
        <group group_id="B3">
          <title>Cohort C</title>
          <description>Participants aged 9 to less than 18 years, who received one or two doses of the 2009 Southern Hemisphere formulation of CSL Limited Influenza Virus Vaccine.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="710"/>
            <count group_id="B2" value="880"/>
            <count group_id="B3" value="402"/>
            <count group_id="B4" value="1992"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="710"/>
                    <measurement group_id="B2" value="880"/>
                    <measurement group_id="B3" value="402"/>
                    <measurement group_id="B4" value="1992"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.84" spread="0.74"/>
                    <measurement group_id="B2" value="5.54" spread="1.66"/>
                    <measurement group_id="B3" value="12.64" spread="2.48"/>
                    <measurement group_id="B4" value="5.66" spread="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="325"/>
                    <measurement group_id="B2" value="439"/>
                    <measurement group_id="B3" value="202"/>
                    <measurement group_id="B4" value="966"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="385"/>
                    <measurement group_id="B2" value="441"/>
                    <measurement group_id="B3" value="200"/>
                    <measurement group_id="B4" value="1026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="710"/>
                    <measurement group_id="B2" value="880"/>
                    <measurement group_id="B3" value="402"/>
                    <measurement group_id="B4" value="1992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency and Intensity of Local and Systemic Solicited Adverse Events, Cohort A (6 Months to Less Than 3 Years)</title>
        <description>Solicited Local Adverse Events: pain, redness, and swelling/induration. Solicited Systemic Adverse Events: fever, headache, myalgia, nausea/vomiting, diarrhea, loss of appetite, and irritability.</description>
        <time_frame>7 days post-vaccination</time_frame>
        <population>The Safety Population comprised all participants who received CSL’s IVV and provided at least one safety assessment after vaccination. For the safety analysis of solicited AEs after the second vaccination, only those participants who received a second vaccination and provided safety follow-up after the second vaccination were included.</population>
        <group_list>
          <group group_id="O1">
            <title>After First Vaccination, Cohort A</title>
            <description>Participants aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O2">
            <title>After Second Vaccination, Cohort A</title>
            <description>Participants aged 6 months to less than 3 years</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Local and Systemic Solicited Adverse Events, Cohort A (6 Months to Less Than 3 Years)</title>
          <description>Solicited Local Adverse Events: pain, redness, and swelling/induration. Solicited Systemic Adverse Events: fever, headache, myalgia, nausea/vomiting, diarrhea, loss of appetite, and irritability.</description>
          <population>The Safety Population comprised all participants who received CSL’s IVV and provided at least one safety assessment after vaccination. For the safety analysis of solicited AEs after the second vaccination, only those participants who received a second vaccination and provided safety follow-up after the second vaccination were included.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="703"/>
                <count group_id="O2" value="615"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local solicited adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254" lower_limit="56.6%" upper_limit="64.0%"/>
                    <measurement group_id="O2" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness (&gt; 0 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness (&gt; 30 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling / induration (&gt; 0 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling / induration (&gt; 30 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic solicited adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="424"/>
                    <measurement group_id="O2" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever (≥99.5°F axillary or ≥100.4 °F oral)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever (≥103.1 F°axillary or ≥104 °F oral)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache (prevent activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia (prevent activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea / vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 nausea / vomiting (prevent activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 diarrhea (prevent activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 loss of appetite (prevent activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295"/>
                    <measurement group_id="O2" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 irritability (prevent activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Unsolicited Adverse Events (UAEs)</title>
        <description>UAE stands for Unsolicited Adverse Event.</description>
        <time_frame>30 days after each study vaccination</time_frame>
        <population>The Safety Population comprised all participants who received CSL's IVV and provided at least one safety assessment after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
          </group>
          <group group_id="O3">
            <title>Cohort C</title>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Unsolicited Adverse Events (UAEs)</title>
          <description>UAE stands for Unsolicited Adverse Event.</description>
          <population>The Safety Population comprised all participants who received CSL's IVV and provided at least one safety assessment after vaccination.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="703"/>
                <count group_id="O2" value="875"/>
                <count group_id="O3" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with at least one UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="531"/>
                    <measurement group_id="O2" value="521"/>
                    <measurement group_id="O3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants reported Grade 1 UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="183"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants reported Grade 2 UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300"/>
                    <measurement group_id="O2" value="251"/>
                    <measurement group_id="O3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants reported Grade 3 UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Local and Systemic Solicited Adverse Events, Cohort A (6 Months to Less Than 3 Years)</title>
        <description>Solicited Local Adverse Events: pain, redness, and swelling/induration. Solicited Systemic Adverse Events: fever, headache, myalgia, nausea/vomiting, diarrhea, loss of appetite, and irritability.</description>
        <time_frame>7 days post-vaccination</time_frame>
        <population>The Safety Population comprised all participants who received CSL’s IVV and provided at least one safety assessment after vaccination. For the safety analysis of solicited AEs after the second vaccination, only those participants who received a second vaccination and provided safety follow-up after the second vaccination were included.</population>
        <group_list>
          <group group_id="O1">
            <title>After First Vaccination, Cohort A</title>
            <description>Participants aged 6 months to less than 3 years</description>
          </group>
          <group group_id="O2">
            <title>After Second Vaccination, Cohort A</title>
            <description>Participants aged 6 months to less than 3 years</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Local and Systemic Solicited Adverse Events, Cohort A (6 Months to Less Than 3 Years)</title>
          <description>Solicited Local Adverse Events: pain, redness, and swelling/induration. Solicited Systemic Adverse Events: fever, headache, myalgia, nausea/vomiting, diarrhea, loss of appetite, and irritability.</description>
          <population>The Safety Population comprised all participants who received CSL’s IVV and provided at least one safety assessment after vaccination. For the safety analysis of solicited AEs after the second vaccination, only those participants who received a second vaccination and provided safety follow-up after the second vaccination were included.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="703"/>
                <count group_id="O2" value="615"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="1.264"/>
                    <measurement group_id="O2" value="1.76" spread="1.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness (&gt; 0 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="1.930"/>
                    <measurement group_id="O2" value="2.74" spread="2.478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling / induration (&gt; 0 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" spread="4.011"/>
                    <measurement group_id="O2" value="3.20" spread="3.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever (≥99.5°F axillary or ≥100.4 °F oral)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="1.164"/>
                    <measurement group_id="O2" value="1.67" spread="1.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="4.492"/>
                    <measurement group_id="O2" value="1.23" spread="0.439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="1.071"/>
                    <measurement group_id="O2" value="1.70" spread="1.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea / vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="2.587"/>
                    <measurement group_id="O2" value="2.84" spread="4.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43" spread="3.473"/>
                    <measurement group_id="O2" value="2.50" spread="2.573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" spread="3.204"/>
                    <measurement group_id="O2" value="3.02" spread="4.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="2.503"/>
                    <measurement group_id="O2" value="2.42" spread="2.726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency and Intensity of Local and Systemic Solicited Adverse Events, Cohort B (3 Years to Less Than 9 Years)</title>
        <description>Solicited Local Adverse Events: pain, redness, and swelling/induration. Solicited Systemic Adverse Events: fever, headache, myalgia, nausea/vomiting, diarrhea, and malaise.</description>
        <time_frame>7 days post-vaccination</time_frame>
        <population>The Safety Population comprised all participants who received CSL’s IVV and provided at least one safety assessment after vaccination. For the safety analysis of solicited AEs after the second vaccination, only those participants who received a second vaccination and provided safety follow-up after the second vaccination were included.</population>
        <group_list>
          <group group_id="O1">
            <title>After First Vaccination, Cohort B</title>
            <description>Participants aged 3 to less than 9 years</description>
          </group>
          <group group_id="O2">
            <title>After Second Vaccination, Cohort B</title>
            <description>Participants aged 3 Years to Less Than 9 Years</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Local and Systemic Solicited Adverse Events, Cohort B (3 Years to Less Than 9 Years)</title>
          <description>Solicited Local Adverse Events: pain, redness, and swelling/induration. Solicited Systemic Adverse Events: fever, headache, myalgia, nausea/vomiting, diarrhea, and malaise.</description>
          <population>The Safety Population comprised all participants who received CSL’s IVV and provided at least one safety assessment after vaccination. For the safety analysis of solicited AEs after the second vaccination, only those participants who received a second vaccination and provided safety follow-up after the second vaccination were included.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="875"/>
                <count group_id="O2" value="634"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local solicited adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="512"/>
                    <measurement group_id="O2" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="463"/>
                    <measurement group_id="O2" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness (&gt; 0 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness (&gt; 30 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling / induration (&gt; 0 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling / induration (&gt; 30 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic solicited adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="346"/>
                    <measurement group_id="O2" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever (≥99.5°F axillary or ≥100.4 °F oral)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever (≥103.1 F°axillary or ≥104 °F oral)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache (prevent activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia (prevent activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea / vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 nausea / vomiting (prevent activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 diarrhea (prevent activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 malaise (prevent activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Local and Systemic Solicited Adverse Events, Cohort B (3 Years to Less Than 9 Years)</title>
        <description>Solicited Local Adverse Events: pain, redness, and swelling/induration. Solicited Systemic Adverse Events: fever, headache, myalgia, nausea/vomiting, diarrhea, and malaise.</description>
        <time_frame>7 days post-vaccination</time_frame>
        <population>The Safety Population comprised all participants who received CSL’s IVV at Visit 1 and provided at least one safety assessment after vaccination. For the safety analysis of solicited AEs after the second vaccination, only those participants who received a second vaccination and provided safety follow-up after the second vaccination were included.</population>
        <group_list>
          <group group_id="O1">
            <title>After First Vaccination, Cohort B</title>
            <description>Participants aged 3 to less than 9 years</description>
          </group>
          <group group_id="O2">
            <title>After Second Vaccination, Cohort B</title>
            <description>Participants aged 3 Years to Less Than 9 Years</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Local and Systemic Solicited Adverse Events, Cohort B (3 Years to Less Than 9 Years)</title>
          <description>Solicited Local Adverse Events: pain, redness, and swelling/induration. Solicited Systemic Adverse Events: fever, headache, myalgia, nausea/vomiting, diarrhea, and malaise.</description>
          <population>The Safety Population comprised all participants who received CSL’s IVV at Visit 1 and provided at least one safety assessment after vaccination. For the safety analysis of solicited AEs after the second vaccination, only those participants who received a second vaccination and provided safety follow-up after the second vaccination were included.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="875"/>
                <count group_id="O2" value="634"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="1.178"/>
                    <measurement group_id="O2" value="1.68" spread="1.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness (&gt; 0 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" spread="1.713"/>
                    <measurement group_id="O2" value="2.21" spread="1.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling / induration (&gt; 0 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" spread="1.688"/>
                    <measurement group_id="O2" value="2.09" spread="1.696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever (≥99.5°F axillary or ≥100.4 °F oral)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="1.114"/>
                    <measurement group_id="O2" value="1.58" spread="1.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="1.373"/>
                    <measurement group_id="O2" value="1.66" spread="1.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="1.264"/>
                    <measurement group_id="O2" value="1.38" spread="0.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea / vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="1.305"/>
                    <measurement group_id="O2" value="1.36" spread="0.757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="1.593"/>
                    <measurement group_id="O2" value="2.00" spread="1.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="1.763"/>
                    <measurement group_id="O2" value="2.13" spread="1.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency and Intensity of Local and Systemic Solicited Adverse Events, Cohort C (9 Years to Less Than 18 Years)</title>
        <description>Solicited Local Adverse Events: pain, redness, and swelling/induration. Solicited Systemic Adverse Events: fever, headache, myalgia, nausea/vomiting, diarrhea, and malaise.</description>
        <time_frame>7 days post-vaccination</time_frame>
        <population>The Safety Population comprised all participants who received CSL’s IVV at Visit 1 and provided at least one safety assessment after vaccination. For the safety analysis of solicited AEs after the second vaccination, only those participants who received a second vaccination and provided safety follow-up after the second vaccination were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort C</title>
            <description>Participants aged 9 to less than 18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Local and Systemic Solicited Adverse Events, Cohort C (9 Years to Less Than 18 Years)</title>
          <description>Solicited Local Adverse Events: pain, redness, and swelling/induration. Solicited Systemic Adverse Events: fever, headache, myalgia, nausea/vomiting, diarrhea, and malaise.</description>
          <population>The Safety Population comprised all participants who received CSL’s IVV at Visit 1 and provided at least one safety assessment after vaccination. For the safety analysis of solicited AEs after the second vaccination, only those participants who received a second vaccination and provided safety follow-up after the second vaccination were included.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local solicited adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness (&gt; 0 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness (&gt; 30 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling / induration (&gt; 0 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling / induration (&gt; 30 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic solicited adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever (≥99.5°F axillary or ≥100.4 °F oral)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever (≥103.1 F°axillary or ≥104 °F oral)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache (prevent activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia (prevent activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea / vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 nausea / vomiting (prevent activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 diarrhea (prevent activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 malaise (prevent activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Local and Systemic Solicited Adverse Events, Cohort C (9 Years to Less Than 18 Years)</title>
        <description>Solicited Local Adverse Events: pain, redness, and swelling/induration. Solicited Systemic Adverse Events: fever, headache, myalgia, nausea/vomiting, diarrhea, and malaise.</description>
        <time_frame>7 days post-vaccination</time_frame>
        <population>The Safety Population comprised all participants who received CSL’s IVV at Visit 1 and provided at least one safety assessment after vaccination. For the safety analysis of solicited AEs after the second vaccination, only those participants who received a second vaccination and provided safety follow-up after the second vaccination were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort C</title>
            <description>Participants aged 9 to less than 18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Local and Systemic Solicited Adverse Events, Cohort C (9 Years to Less Than 18 Years)</title>
          <description>Solicited Local Adverse Events: pain, redness, and swelling/induration. Solicited Systemic Adverse Events: fever, headache, myalgia, nausea/vomiting, diarrhea, and malaise.</description>
          <population>The Safety Population comprised all participants who received CSL’s IVV at Visit 1 and provided at least one safety assessment after vaccination. For the safety analysis of solicited AEs after the second vaccination, only those participants who received a second vaccination and provided safety follow-up after the second vaccination were included.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="1.317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness (&gt; 0 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" spread="1.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling / induration (&gt; 0 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.81" spread="1.854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever (≥99.5°F axillary or ≥100.4 °F oral)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="0.415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="1.851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.20" spread="3.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea / vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="1.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="1.771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="1.853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Serious Adverse Events</title>
        <time_frame>180 days after the last study vaccination</time_frame>
        <population>The Safety Population comprised all participants who received CSL's IVV and provided at least one safety assessment after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
          </group>
          <group group_id="O3">
            <title>Cohort C</title>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Serious Adverse Events</title>
          <population>The Safety Population comprised all participants who received CSL's IVV and provided at least one safety assessment after vaccination.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="703"/>
                <count group_id="O2" value="875"/>
                <count group_id="O3" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with at least one SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of New Onsets of Chronic Illness</title>
        <time_frame>180 days after the last study vaccination</time_frame>
        <population>The Safety Population comprised all participants who received CSL's IVV and provided at least one safety assessment after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
          </group>
          <group group_id="O3">
            <title>Cohort C</title>
          </group>
        </group_list>
        <measure>
          <title>Frequency of New Onsets of Chronic Illness</title>
          <population>The Safety Population comprised all participants who received CSL's IVV and provided at least one safety assessment after vaccination.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="703"/>
                <count group_id="O2" value="875"/>
                <count group_id="O3" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with at least one NOCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with related NOCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs were collected up to 180 days after the last study vaccination. Other adverse events were unsolicited adverse events that were collected up to 30 days after the study vaccination.</time_frame>
      <desc>Other adverse events were unsolicited adverse events that were collected up to 30 days after the study vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort A</title>
          <description>Participants aged 6 months to less than 3 years, who received one or two doses of the 2009 Southern Hemisphere formulation of CSL Limited Influenza Virus Vaccine.</description>
        </group>
        <group group_id="E2">
          <title>Cohort B</title>
          <description>Participants aged 3 to less than 9 years, who received one or two doses of the 2009 Southern Hemisphere formulation of CSL Limited Influenza Virus Vaccine.</description>
        </group>
        <group group_id="E3">
          <title>Cohort C</title>
          <description>Participants aged 9 to less than 18 years, who received one or two doses of the 2009 Southern Hemisphere formulation of CSL Limited Influenza Virus Vaccine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="875"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="875"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="875"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvi-ureteric obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="703"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="531" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="467" subjects_at_risk="875"/>
                <counts group_id="E3" subjects_affected="97" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" events="165" subjects_affected="113" subjects_at_risk="703"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="875"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="53" subjects_affected="46" subjects_at_risk="703"/>
                <counts group_id="E2" events="27" subjects_affected="26" subjects_at_risk="875"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="95" subjects_affected="76" subjects_at_risk="703"/>
                <counts group_id="E2" events="58" subjects_affected="55" subjects_at_risk="875"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="262" subjects_affected="208" subjects_at_risk="703"/>
                <counts group_id="E2" events="171" subjects_affected="142" subjects_at_risk="875"/>
                <counts group_id="E3" events="37" subjects_affected="33" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="59" subjects_affected="50" subjects_at_risk="703"/>
                <counts group_id="E2" events="46" subjects_affected="39" subjects_at_risk="875"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="41" subjects_affected="37" subjects_at_risk="703"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="875"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" events="38" subjects_affected="31" subjects_at_risk="875"/>
                <counts group_id="E3" events="37" subjects_affected="33" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="97" subjects_affected="80" subjects_at_risk="703"/>
                <counts group_id="E2" events="101" subjects_affected="86" subjects_at_risk="875"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="111" subjects_affected="90" subjects_at_risk="703"/>
                <counts group_id="E2" events="73" subjects_affected="65" subjects_at_risk="875"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="40" subjects_affected="36" subjects_at_risk="703"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="875"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Study Disclosure Manager</name_or_title>
      <organization>Seqirus</organization>
      <phone>1-855-358-8966</phone>
      <email>Seqirus.ClinicalTrials@Seqirus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

